$0.7116
-0.00840-1.17%
At close: -
$0.7300
0.022.59%
After Hours: 7:58 PM EDT
Comments
Loading...
Tempest Therapeutics (TPST) Forecast
NewsEarningsTempest Therapeutics (TPST) OptionsGuidanceDividendsAnalyst RatingsInsider TradesShort InterestTempest Therapeutics (NASDAQ:TPST) Stock Quotes, Forecast and News Summary
Tempest Therapeutics Stock (NASDAQ: TPST) stock price, news, charts, stock research, profile.
Compare
EPS worse than industry
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.
EPS worse than industry
FAQ
How do I buy Tempest Therapeutics (TPST) stock?
You can purchase shares of Tempest Therapeutics (NASDAQ:TPST) through any online brokerage.
Who are Tempest Therapeutics (TPST) competitors?
Other companies in Tempest Therapeutics’s space includes: Outlook Therapeutics (NASDAQ:OTLK), HOOKIPA Pharma (NASDAQ:HOOK), Intensity Therapeutics (NASDAQ:INTS), Curis (NASDAQ:CRIS) and FibroGen (NASDAQ:FGEN).
What is the forecast, or price target, for Tempest Therapeutics (TPST) stock?
Tempest Therapeutics has a consensus price target of $18.80.
What is the current price for Tempest Therapeutics (TPST)?
The stock price for Tempest Therapeutics (NASDAQ: TPST) is $0.73 last updated December 20, 2024 at 7:58 PM EST.
Does Tempest Therapeutics (TPST) pay a dividend?
There are no upcoming dividends for Tempest Therapeutics.
When is Tempest Therapeutics (NASDAQ:TPST) reporting earnings?
Tempest Therapeutics’s Q4 earnings are confirmed for Tuesday, March 18, 2025.
Is Tempest Therapeutics (TPST) going to split?
There is no upcoming split for Tempest Therapeutics.
What sector and industry does Tempest Therapeutics (TPST) operate in?
Tempest Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.